In recent trading, shares of Victory Capital Holdings Inc (Symbol: VCTR) have crossed above the average analyst 12-month target price of $110.33, changing hands for $110.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: d
(RTTNews) - The French stock market's benchmark index CAC 40 slipped into negative territory on Wednesday, failing to hold early gains, as oil prices climbed higher on supply concerns amid lingering uncertainty about Iran and U.S. reaching a deal to end their conflict anytime soo
(RTTNews) - The following biotech stocks reached a 52-week high on September 29, 2026, driven by key catalysts such as promising results from clinical trials or revised financial guidance.
(RTTNews) - On Wednesday Pyxis Oncology (PYXS), a clinical-stage biopharmaceutical, announced the pricing of its previously announced public offering, expected to generate approximately $110 million in gross proceeds.
(RTTNews) - After moving notably higher Wednesday morning, German stocks pared gains as oil prices turned higher, rebounding from a sharp fall in the previous session.
(RTTNews) - FibroBiologics, Inc. (FBLG), a clinical-stage biotechnology company, announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity," covering its fibroblast therapeutic technology.
(RTTNews) - Atossa Therapeutics (ATOS) announced that its Board has approved a plan to issue one contingent value right (CVR) for each share of common stock, linking shareholders to potential proceeds from the company's first qualifying Rare Pediatric Disease Priority Review Vouc
(RTTNews) - Liminatus Pharma, Inc. (LIMN), a biotechnology company developing immuno-oncology and cell therapy candidates, announced that it has regained compliance with Nasdaq's minimum bid price rule.